Mary Lynne Hedley
CIK 1340823 · President & COO · last filed 2026-06-24
Mary Lynne Hedley is a President & COO who has filed 118 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.44M
8
118
-$1.06M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Director | — | $40.50 | — | $0 | 5 | 2026-06-24 |
| VEEV | Director | 7,152 | $230.47 | $1.65M | -$146.4K | 42 | 2026-06-22 |
| LLY | Director | 2,350 | $1185.71 | $2.79M | $0 | 44 | 2025-12-16 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | — | $15.90 | — | $0 | 4 | 2020-06-23 |
| TESARO, Inc. (TSRO) Delisted | President & COO | 0 | — | — | -$909.0K | 10 | 2019-01-22 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 185 | $4.97 | $919 | $0 | 2 | 2018-06-22 |
| Receptos, Inc. (RCPT) Delisted | Director | 0 | — | — | $0 | 2 | 2015-08-27 |
| MGI PHARMA INC (MOGN) Delisted | Exec VP & Chief Scientific Off | 18,250 | — | — | $0 | 5 | 2008-01-25 |
Recent Filings
118 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | Centessa Pharmaceuticals plc (CNTA) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-06-22 | VEEV | Grant (A) | — | $0 | EDGAR |
| 2026-06-03 | VEEV | Exer (M) | +262 | $0 | EDGAR |
| 2026-03-03 | VEEV | Exer (M) | +262 | $0 | EDGAR |
| 2025-12-16 | LLY | Grant (A) | +9 | $9.9K | EDGAR |
| 2025-12-02 | VEEV | Exer (M) | +263 | $0 | EDGAR |
| 2025-11-18 | LLY | Grant (A) | +225 | $229.9K | EDGAR |
| 2025-10-22 | LLY | Grant (A) | +12 | $9.9K | EDGAR |
| 2025-09-17 | LLY | Grant (A) | +13 | $9.9K | EDGAR |
| 2025-09-03 | VEEV | Exer (M) | +262 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.